Author(s):
Islam Hamad, Amani A. Harb, Eman Y. Abu-Rish, Shereen M. Aleidi, Ola Sallam, Haneen El-Huneidi, Bashar Alkhalidi, Mohammad Mohammad, Mohammad H. Semreen, Eman Abu-Gharbieh, Yasser Bustanji
Email(s):
ybustanji@sharjah.ac.ae , i.hamad@aum.edu.jo
DOI:
10.52711/0974-360X.2025.00226 
Address:
Islam Hamad1*, Amani A. Harb2, Eman Y. Abu-Rish3, Shereen M. Aleidi3, Ola Sallam3, Haneen El-Huneidi4, Bashar Alkhalidi3, Mohammad Mohammad5, Mohammad H. Semreen6,7, Eman Abu-Gharbieh6,8,3, Yasser Bustanji6,8,3*
1Department of Pharmacy, Faculty of Health Sciences, American University of Madaba, Amman, Jordan.
2Department of Basic Sciences, Faculty of Arts and Sciences, Al-Ahliyya Amman University, Amman, Jordan.
3School of Pharmacy, The University of Jordan, Amman 11942 Jordan.
4Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
5SANA Pharma company, Amman, Jordan.
6Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
7College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
8College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.
*Corresponding Author
Published In:
Volume - 18,
Issue - 4,
Year - 2025
ABSTRACT:
The hepatic protein Mannose-binding lectin (MBL) serves a pivotal role in the acute-phase immune response, potentially influencing the pathogenesis of type 2 diabetes (T2DM) and its associated complications, such as nephropathy and retinopathy. Recent evidence suggests that elevated plasma MBL levels may serve as a predictive marker for albuminuria in T2DM patients. Moreover, it is postulated that MBL ligands are present within the kidneys of diabetic individuals, thereby facilitating the deposition of MBL within the renal parenchyma or other target organs, thereby exacerbating pathological processes. This study aimed to assess serum MBL levels in T2DM patients and explore potential associations between MBL levels and the onset of diabetic complications. A cross-sectional investigation was conducted, encompassing 92 participants, comprising 71 individuals diagnosed with T2DM and 21 age- and sex-matched healthy counterparts. Among the T2DM cohort, patients were stratified into nephropathic and non-nephropathic subgroups based on the presence of nephropathy, as well as into subgroups with or without retinopathy based on retinopathy status. Serum MBL levels were quantified utilizing Enzyme-Linked Immunosorbent Assay (ELISA). The mean MBL levels were found to be significantly elevated in diabetic patients compared to healthy controls (1736 vs. 730.99 ng/mL, p-value = 0.011). Furthermore, MBL levels exhibited a statistically significant increase in individuals with microalbuminuria compared to normoalbuminuric T2DM patients (p-value = 0.019). Notably, a significant association was observed between heightened MBL levels in diabetic patients and the occurrence of retinopathy. The findings of this study support the hypothesis implicating MBL in the pathogenesis of T2DM and the initiation and progression of its associated complications, including nephropathy and retinopathy. Nevertheless, further investigation is warranted to delineate the precise underlying mechanisms governing the relationship between MBL and T2DM pathophysiology.
Cite this article:
Islam Hamad, Amani A. Harb, Eman Y. Abu-Rish, Shereen M. Aleidi, Ola Sallam, Haneen El-Huneidi, Bashar Alkhalidi, Mohammad Mohammad, Mohammad H. Semreen, Eman Abu-Gharbieh, Yasser Bustanji. Elevated Levels of Mannose-Binding Lectin (MBL) in patients with Type 2 Diabetes and its Potential Association with Nephropathy and Retinopathy. Research Journal of Pharmacy and Technology. 2025;18(4):1579-6. doi: 10.52711/0974-360X.2025.00226
Cite(Electronic):
Islam Hamad, Amani A. Harb, Eman Y. Abu-Rish, Shereen M. Aleidi, Ola Sallam, Haneen El-Huneidi, Bashar Alkhalidi, Mohammad Mohammad, Mohammad H. Semreen, Eman Abu-Gharbieh, Yasser Bustanji. Elevated Levels of Mannose-Binding Lectin (MBL) in patients with Type 2 Diabetes and its Potential Association with Nephropathy and Retinopathy. Research Journal of Pharmacy and Technology. 2025;18(4):1579-6. doi: 10.52711/0974-360X.2025.00226 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-4-17
REFERENCES:
1. Worthley DL, Bardy PG, Mullighan CG. Mannose-binding lectin: Biology and clinical implications. Intern Med J. 2005; 35(9): 548-55.
2. Gupta A, Gupta GS. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. Mol Cell Biochem. 2021; 476(8): 2917-42.
3. Muss, T. Q.; Al-Faham, M.; Gorial, F. I.; Zghair, A. K., Galectin-8 gene polymorphism among Iraqi patients with rheumatoid arthritis. Res. J. Pharm. Technol. 2019; 12(4): 1643-1645.
4. Bouwman LH, Roep BO, Roos A. Mannose-Binding Lectin: Clinical Implications for Infection, Transplantation, and Autoimmunity. Hum Immunol. 2006; 67(4-5): 247-56.
5. Gedebjerg A, Bjerre M, Kjaergaard AD, et al. Mannose-binding lectin and risk of cardiovascular events and mortality in type 2 diabetes: A Danish cohort study. Diabetes Care. 2020; 43(9): 2190-8.
6. Swierzko AS, Szala A, Sawicki S, et al. Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours. Cancer Immunol Immunother. 2014; 63(11): 1129-40.
7. Ma Y, Cai F, Huang X, et al. Mannose-binding lectin activates the nuclear factor-κB and renal inflammation in the progression of diabetic nephropathy. FASEB J. 2022; 36(3).
8. Yu TH, Wu CC, Tsai IT, et al. Circulating mannose-binding lectin concentration in patients with stable coronary artery disease is associated with heart failure and renal function. Clin Chim Acta. 2023; 548.
9. Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol. 2008; 46(2): 225-32.
10. Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, Moghimi SM. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: Implications for stealth nanoparticle engineering. ACS Nano. 2010; 4(11): 6629-38.
11. Hamad I, Hunter AC, Moghimi SM. Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. J Control Release. 2013; 170(2): 167-74.
12. IDF. International Diabetes Federation. IDF Diabetes Atlas. 10th Edition. Brussels, Belgium, 2023 https://diabetesatlas.org/. 2023.
13. USRD. United States Renal Data System. 2022 USRDS Annual Data Report: End-Stage Renal Disease (ESRD) in the United States, 2020. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022. https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease. 2022.
14. Jaiswal, A.; Semwal, B. C.; Singh, S., A Compressive Review on Novel Molecular Target of Diabetic Nephropathy. Res. J. Pharm. Technol. 2022; 15(3): 1398-1404.
15. Li XQ, Chang DY, Chen M, Zhao MH. Complement activation in patients with diabetic nephropathy. Diabetes Metab. 2019; 45(3): 248-53.
16. Hansen TK, Tarnow L, Thiel S, et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes. 2004; 53(6): 1570-6.
17. Jiang S, Jiao Y, Zou G, Gao H, Zhuo L, Li W. Activation of Complement Pathways in Kidney Tissue May Mediate Tubulointerstitial Injury in Diabetic Nephropathy. Front Med 2022; 9.
18. Akour A, Kasabri V, Boulatova N, et al. Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. Acta Diabetol. 2017; 54(2): 163-70.
19. Hovind P, Hansen TK, Tarnow L, et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: An inception cohort study. Diabetes. 2005; 54(5): 1523-7.
20. Zhang N, Zhuang M, Ma A, et al. Association of levels of Mannose-binding lectin and the MBL2 gene with type 2 diabetes and diabetic nephropathy. PLoS ONE. 2013; 8(12).
21. Dørflinger GH, Høyem PH, Laugesen E, et al. High MBL-expressing genotypes are associated with deterioration in renal function in type 2 diabetes. Front Immunol. 2022; 13.
22. Hansen TK, Forsblom C, Saraheimo M, et al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia. 2010; 53(7): 1517-24.
23. Garred P, Genster N, Pilely K, et al. A journey through the lectin pathway of complement—MBL and beyond. Immunol Rev. 2016; 274(1): 74-97.
24. Musunuri B, Tripathy R, Padhi S, Panda AK, Das BK. The role of MBL, PCT, CRP, neutrophil–lymphocyte ratio, and platelet lymphocyte ratio in differentiating infections from flares in lupus. Clin Rheumatol. 2022; 41(11): 3337-44.
25. Holt CB, Hoffmann-Petersen IT, Hansen TK, et al. Association between severe diabetic retinopathy and lectin pathway proteins – an 18-year follow-up study with newly diagnosed type 1 diabetes patients. Immunobiology. 2020; 225(3).
26. Hokazono K, Belizário FS, Portugal V, Messias-Reason I, Nisihara R. Mannose Binding Lectin and Pentraxin 3 in Patients with Diabetic Retinopathy. Arch Med Res. 2018; 49(2): 123-9.
27. Huang Q, Shang G, Deng H, Liu J, Mei Y, Xu Y. High mannose-binding lectin serum levels are associated with diabetic retinopathy in Chinese patients with type 2 diabetes. PLoS ONE. 2015; 10(7).
28. Al-Rawashdeh A, Kasabri V, Bulatova N, et al. The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: A cross sectional study from Jordan. Diabetes Metab Syndr Clin Res Rev. 2017; 11(1): 59-67.
29. Aleidi SM, Shayeb E, Bzour J, et al. Serum level of insulin-like growth factor-I in type 2 diabetic patients: impact of obesity. Horm Mol Biol Clin Invest. 2019; 39(1).
30. Kaur, H.; Kaur, A.; Prashar, P. K.; Gautam, A.; Sood, A.; Singh, S. K.; Gulati, M.; Pandey, N. K.; Kumar, B., Clinical impact of combination therapy in diabetic neuropathy and nephropathy. Res. J. Pharm. Technol. 2021; 14(6): 3471-3480.
31. Sandeep Goyal, V.K. Bansal, Dhruba Sankar Goswami, Suresh Kumar. Vascular Endothelial Dysfunction: Complication of Diabete Mellitus and Hyperhomocysteinemia. Research J. Pharm. and Tech. 2010; 3: (3): 657-664.
32. Naveen K L, Grinton Josvi Veigas, Ananya Bhattacharjee. Patient with Diabetes Mellitus and Ocular Complications: A Brief review. Asian Journal of Pharmacy and Technology. 2021; 11(2): 141-5.
33. Shilpa. S. Risk Status of Lower Extremity Arterial Disease (LEAD) among persons with Diabetes Mellitus. Int. J. of Advances in Nur. Management. 2019; 7(1): 13-19.
34. Rosu LM, Prodan-Bărbulescu C, Maghiari AL, et al. Current Trends in Diagnosis and Treatment Approach of Diabetic Retinopathy during Pregnancy: A Narrative Review. Diagn. 2024; 14(4).
35. Smith JM, Mandava N, Tirado-Gonzalez V, et al. Correlation of Complement Activation in Aqueous and Vitreous in Patients With Proliferative Diabetic Retinopathy. Translational Vis Sci Technol. 2022; 11(4).
36. Pan WW, Lin F, Fort PE. The innate immune system in diabetic retinopathy. Prog Retinal Eye Res. 2021; 84.
37. Shahulhameed S, Vishwakarma S, Chhablani J, et al. A Systematic Investigation on Complement Pathway Activation in Diabetic Retinopathy. Front Immunol. 2020; 11.
38. Mao Y, Wei H, Gong Y, Peng L, Chen Y. Association of MBL2 gene polymorphisms and MBL levels with dilated cardiomyopathy in a Chinese Han population. BMC Med Genomics. 2024; 17(1).
39. Kapetanovic MC, Lindqvist E, Sturfelt G, Saxne T, Truedsson L, Eberhardt K. The impact of IL-1Ra and MBL gene polymorphisms on joint damage after 5 and 10 years in patients with early rheumatoid arthritis. J Rheumatol. 2007; 34(4): 894-5.
40. Pehlivan M, Sahin HH, Ozdilli K, et al. Gene polymorphisms and febrile neutropenia in acute leukemia-no association with IL-4, CCR-5, IL-1RA, but the MBL-2, ACE, and TLR-4 are associated with the disease in Turkish patients: A preliminary study. Gent Test and Mol Biomarkers. 2014; 18(7): 474-81.
41. Frauenknecht V, Thiel S, Storm L, et al. Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clin Exp Immunol. 2013; 173(1): 112-20.
42. Speletas M, Dadouli K, Syrakouli A, et al. MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19. Immunobiology. 2021; 226(6).
43. Daifallah OS, Fouad AM, Ali RH. Diagnostic potential of mannose binding lectin (MBL) gene polymorphism in rheumatoid arthritis patients. Egypt Rheumatol. 2021; 43(1): 13-6.
44. S. Sivaprasad. Epidemiological Study on complications of Diabetes and its Treatment Options. Asian Journal of Pharmacy and Technology. 2022; 12(1): 38-0.
45. Akour A, Kasabri V, Bulatova N, et al. Association of oxytocin with glucose intolerance and inflammation biomarkers in metabolic syndrome patients with and without prediabetes. Rev Diabetic Stud 2017; 14(4): 364-71.
46. Aleidi S, Issa A, Bustanji H, Khalil M, Bustanji Y. Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients. Saudi Pharm J. 2015; 23(3): 250-6.
47. Pavithra, D.; Praveen, D.; Vijey Aanandhi, M., A comprehensive review on biomarkers for assessing diabetic kidney disease. Res. J. Pharm. Technol. 2017; 10(9): 3242-3246.
48. Al Saudi RM, Kasabri V, Naffa R, Bulatova N, Bustanji Y. Glycated LDL-C and glycated HDL-C in association with adiposity, blood and atherogenicity indices in metabolic syndrome patients with and without prediabetes. Ther Adv Endocrinol Metab. 2018; 9(10): 311-23.
49. Al-Musa K, Kasabri V, Bulatova N, et al. Correlations of oxytocin, fibroblast growth factor-21 and hepatocyte growth factor in diabetic and non-diabetic metabolic syndrome patients: Acase- control study from Jordan. Jordan J Pharm. 2019; 12(2): 69-89.
50. Al-Nouaaimi MM, Kasabri V, Akour A, et al. Evaluation of the correlation of oxytocin plasma levels and metabolic syndrome biomarkers (Leptin, adiponectin and resistin) in newly diagnosed type 2 diabetes patients in Jordan: A cross sectional study. Jordan J Pharm. 2016; 9(2): 115-28.
51. Sildorf SM, Eising S, Hougaard DM, et al. Differences in MBL levels between juvenile patients newly diagnosed with type 1 diabetes and their healthy siblings. Mol Immunol. 2014; 62(1): 71-6.
52. Kildey K, Rooks K, Weier S, Flower RL, Dean MM. Effect of age, gender and mannose-binding lectin (MBL) status on the inflammatory profile in peripheral blood plasma of Australian blood donors. Hum Immunol. 2014; 75(9): 973-9.
53. Ip WK, To YF, Cheng SK, Lau YL. Serum mannose-binding lectin levels and mbl2 gene polymorphisms in different age and gender groups of southern Chinese adults. Scand J Immunol. 2004; 59(3): 310-4.
54. Rupashri, S. V.; Gheena, S., Recent advances in diabetes research. Res. J. Pharm. Technol. 2016, 9, (10), 1806-1808
55. Roshani Bhalerao, Akshay Patil, Dinesh Rishipathak, Sanjay Kshirsagar. Insulin Therapies: Current and Future Trends. Asian J. Res. Pharm. Sci. 2017; 7(4): 189-196. doi: 10.5958/2231-5659.2017.00029.7